FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217191787> ?p ?o ?g. }

• W3217191787 endingPage "7502" @default.
• W3217191787 startingPage "7494" @default.
• W3217191787 abstract "A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the 13-valent pneumococcal conjugate vaccine, PCV13, and includes capsular polysaccharide conjugates for 7 additional serotypes. Thus, PCV20 may cover those additional serotypes in individuals previously vaccinated with PCV13 or provide benefits of immunization with a conjugate vaccine to individuals previously immunized with a pneumococcal polysaccharide vaccine. This study described the safety and immunogenicity of PCV20 in adults ≥65 years of age with prior pneumococcal vaccination.This phase 3, multicenter, randomized, open-label study was conducted in the United States and Sweden. Adults ≥65 years of age were enrolled into 1 of 3 cohorts based on their prior pneumococcal vaccination history (23-valent pneumococcal polysaccharide vaccine [PPSV23], PCV13, or both PCV13 and PPSV23). Participants were randomized 2:1 within their cohort to receive a single dose of PCV20 or PCV13 in those with prior PPSV23 only, and PCV20 or PPSV23 in those with prior PCV13 only; all participants with prior PCV13 and PPSV23 received PCV20. Safety was assessed by prompted local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 1 month, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination. Immune responses 1 month after PCV20 were assessed.The percentages of participants reporting local reactions, systemic events, and AEs after PCV20 administration were similar across cohorts and comparable with the PCV13 and PPSV23 control groups. SAE and NDCMC rates were low in all groups. Robust immune responses, including opsonophagocytic antibody responses, to the 20 vaccine serotypes were observed 1 month after PCV20 regardless of prior pneumococcal vaccination.PCV20 was well tolerated and immunogenic in adults ≥65 years of age previously vaccinated with different pneumococcal vaccine regimens. Clinicaltrials.gov NCT03835975." @default.
• W3217191787 created "2021-12-06" @default.
• W3217191787 creator A5029133374 @default.
• W3217191787 creator A5034298673 @default.
• W3217191787 creator A5037149799 @default.
• W3217191787 creator A5038747877 @default.
• W3217191787 creator A5044292989 @default.
• W3217191787 creator A5055769260 @default.
• W3217191787 creator A5058719610 @default.
• W3217191787 creator A5066245741 @default.
• W3217191787 creator A5086524484 @default.
• W3217191787 creator A5089678920 @default.
• W3217191787 date "2021-12-01" @default.
• W3217191787 modified "2023-10-03" @default.
• W3217191787 title "A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination" @default.
• W3217191787 cites W1456171542 @default.
• W3217191787 cites W186835318 @default.
• W3217191787 cites W1920731750 @default.
• W3217191787 cites W1954112402 @default.
• W3217191787 cites W1963985157 @default.
• W3217191787 cites W2000714505 @default.
• W3217191787 cites W2025268611 @default.
• W3217191787 cites W2028959386 @default.
• W3217191787 cites W2031120479 @default.
• W3217191787 cites W2042944880 @default.
• W3217191787 cites W2091773960 @default.
• W3217191787 cites W2092545077 @default.
• W3217191787 cites W2113682359 @default.
• W3217191787 cites W2138554949 @default.
• W3217191787 cites W2166448515 @default.
• W3217191787 cites W2174465621 @default.
• W3217191787 cites W2274717124 @default.
• W3217191787 cites W2285890775 @default.
• W3217191787 cites W2293032522 @default.
• W3217191787 cites W2345670660 @default.
• W3217191787 cites W2581775754 @default.
• W3217191787 cites W2606215982 @default.
• W3217191787 cites W2613751645 @default.
• W3217191787 cites W2729767968 @default.
• W3217191787 cites W2746698216 @default.
• W3217191787 cites W2889338154 @default.
• W3217191787 cites W2889562406 @default.
• W3217191787 cites W2909558837 @default.
• W3217191787 cites W2911774885 @default.
• W3217191787 cites W2913664322 @default.
• W3217191787 cites W2916628897 @default.
• W3217191787 cites W2944691089 @default.
• W3217191787 cites W2964469325 @default.
• W3217191787 cites W3076065805 @default.
• W3217191787 cites W3120274840 @default.
• W3217191787 cites W4294350673 @default.
• W3217191787 doi "https://doi.org/10.1016/j.vaccine.2021.10.032" @default.
• W3217191787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34839993" @default.
• W3217191787 hasPublicationYear "2021" @default.
• W3217191787 type Work @default.
• W3217191787 sameAs 3217191787 @default.
• W3217191787 citedByCount "27" @default.
• W3217191787 countsByYear W32171917872022 @default.
• W3217191787 countsByYear W32171917872023 @default.
• W3217191787 crossrefType "journal-article" @default.
• W3217191787 hasAuthorship W3217191787A5029133374 @default.
• W3217191787 hasAuthorship W3217191787A5034298673 @default.
• W3217191787 hasAuthorship W3217191787A5037149799 @default.
• W3217191787 hasAuthorship W3217191787A5038747877 @default.
• W3217191787 hasAuthorship W3217191787A5044292989 @default.
• W3217191787 hasAuthorship W3217191787A5055769260 @default.
• W3217191787 hasAuthorship W3217191787A5058719610 @default.
• W3217191787 hasAuthorship W3217191787A5066245741 @default.
• W3217191787 hasAuthorship W3217191787A5086524484 @default.
• W3217191787 hasAuthorship W3217191787A5089678920 @default.
• W3217191787 hasConcept C126322002 @default.
• W3217191787 hasConcept C197934379 @default.
• W3217191787 hasConcept C203014093 @default.
• W3217191787 hasConcept C22070199 @default.
• W3217191787 hasConcept C2776152631 @default.
• W3217191787 hasConcept C2778866548 @default.
• W3217191787 hasConcept C2779301066 @default.
• W3217191787 hasConcept C2779664119 @default.
• W3217191787 hasConcept C2780868878 @default.
• W3217191787 hasConcept C2781253189 @default.
• W3217191787 hasConcept C3020803494 @default.
• W3217191787 hasConcept C501593827 @default.
• W3217191787 hasConcept C71924100 @default.
• W3217191787 hasConcept C86803240 @default.
• W3217191787 hasConcept C8891405 @default.
• W3217191787 hasConcept C89423630 @default.
• W3217191787 hasConceptScore W3217191787C126322002 @default.
• W3217191787 hasConceptScore W3217191787C197934379 @default.
• W3217191787 hasConceptScore W3217191787C203014093 @default.
• W3217191787 hasConceptScore W3217191787C22070199 @default.
• W3217191787 hasConceptScore W3217191787C2776152631 @default.
• W3217191787 hasConceptScore W3217191787C2778866548 @default.
• W3217191787 hasConceptScore W3217191787C2779301066 @default.
• W3217191787 hasConceptScore W3217191787C2779664119 @default.
• W3217191787 hasConceptScore W3217191787C2780868878 @default.
• W3217191787 hasConceptScore W3217191787C2781253189 @default.
• W3217191787 hasConceptScore W3217191787C3020803494 @default.
• W3217191787 hasConceptScore W3217191787C501593827 @default.

• next